Eiger Appoints New Executive Leadership
Rose Nor
Eiger BioPharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, has appointed Christopher Kurtz as chief technical officer and Sarah Mathieson as senior vice president, Corporate Affairs.
"This is a pivotal year for Eiger, and I am pleased to welcome Chris and Sarah to the leadership team as our company continues to build momentum across our late-stage pipeline," said David Cory, president and chief executive officer. "We are making great progress advancing our lead clinical programs in Hepatitis Delta Virus infection and expect topline data from the Phase 3 D-LIVR study by end of 2022. In addition, we recently announced positive topline data from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19 and are actively working on an Emergency Use Authorization submission.”
“Expanding our leadership team with technical operations and corporate communications expertise is critical as we advance multiple, novel, first-in-class therapeutics to improve the lives of patients with serious diseases,” Cory added.
